Search Results for "data"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for data. Results 331 to 340 of 1119 total matches.
In Brief: Brexucabtagene autoleucel (Tecartus) for Acute Lymphoblastic Leukemia (online only)
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
breastfeeding. There are no
data on the presence of brexucabtagene autoleucel
in human breast milk or its ...
Brexucabtagene autoleucel (Tecartus – Kite) has
been approved by the FDA for treatment of adults
with relapsed or refractory B-cell precursor acute
lymphoblastic leukemia (ALL). It was previously
approved for treatment of relapsed or refractory
mantle cell lymphoma. Tecartus is an individualized
cellular product prepared from the patients own
T cells, which are genetically modified to express
chimeric antigen receptors (CAR) and then infused
back into the patient. The CAR T-cell immunotherapy
tisagenlecleucel (Kymriah) was approved in 2017 for
treatment of relapsed or refractory...
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e105-6 doi:10.58347/tml.2023.1678f | Show Introduction Hide Introduction
In Brief: Casgevy for Beta Thalassemia
The Medical Letter on Drugs and Therapeutics • May 13, 2024 (Issue 1702)
-arm trial (CLIMB THAL-111) in 52 patients
(only 35 had sufficient follow-up data) 12 to 35 years
1 ...
Exagamglogene autotemcel (Casgevy – Vertex), a cell-based
gene therapy recently approved for treatment
of sickle cell disease1, has now been approved by
the FDA for treatment of patients ≥12 years old with
transfusion-dependent beta thalassemia. Casgevy is
the first gene therapy that uses CRISPR/Cas9 gene-editing
technology to be approved in the US for any
disorder. Betibeglogene autotemcel (Zynteglo), an
autologous lentiviral vector cell-based gene therapy,
was approved in the US in 2022 for treatment of
transfusion-dependent beta thalassemia.
Med Lett Drugs Ther. 2024 May 13;66(1702):79 doi:10.58347/tml.2024.1702d | Show Introduction Hide Introduction
In Brief: Doxycycline for STI Post-Exposure Prophylaxis
The Medical Letter on Drugs and Therapeutics • Jul 22, 2024 (Issue 1707)
STUDIES — Issuance of the new recommendation was based on data from three randomized, open-label trials ...
The CDC has issued a recommendation for use
of a single dose of doxycycline for post-exposure
prophylaxis (PEP) of bacterial sexually transmitted
infections (STIs), specifically syphilis, chlamydia, and
gonorrhea, in men who have sex with men (MSM) and
transgender women (TGW) who had a bacterial STI
within the previous 12 months.
Med Lett Drugs Ther. 2024 Jul 22;66(1707):119-20 doi:10.58347/tml.2024.1707f | Show Introduction Hide Introduction
Revakinagene Taroretcel (Encelto) – A Gene Therapy for Idiopathic Macular Telangiectasia (online only)
The Medical Letter on Drugs and Therapeutics • Apr 28, 2025 (Issue 1727)
24 months was significantly lower with Encelto
than with sham treatment in both trials. Data beyond ...
Revakinagene taroretcel-lwey (Encelto – Neurotech),
an intravitreal allogeneic cell-based gene therapy, has
been approved by the FDA for treatment of idiopathic
macular telangiectasia type 2 in adults. It is the first
treatment to be approved in the US for this indication.
Med Lett Drugs Ther. 2025 Apr 28;67(1727):e74 doi:10.58347/tml.2025.1727f | Show Introduction Hide Introduction
Adult Immunization
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022 (Issue 1661)
inactivated influenza vaccine is recommended.
4. For PCV15 or PCV20, no data are available. For PPSV23 ...
The Advisory Committee on Immunization Practices
(ACIP) recommends use of certain vaccines in adults
residing in the US. Routine childhood immunization
has reduced the overall incidence of some of
these vaccine-preventable diseases, but many
adults remain susceptible. Recommendations for
vaccination against COVID-19, seasonal influenza,
and monkeypox and vaccination of travelers have
been reviewed separately.
Safe Needles
The Medical Letter on Drugs and Therapeutics • Apr 05, 1991 (Issue 841)
blunting mechanisms might
decrease transmission of infection by accidental needlestick, but no data ...
Accidental needlesticks can lead to infection with hepatitis viruses, human immunodeficiency virus, and other blood-borne bacterial, viral, and fungal pathogens (DK Henderson et al, Ann Intern Med, 113:740, 1990). Re-capping used needles is the most frequent cause of needlestick injuries (J Jagger et al, N Engl J Med, 319:284, 1988; MH Becker et al, Am J Infect Control, 18:232, 1990).
Masoprocol for Multiple Actinic Keratoses
The Medical Letter on Drugs and Therapeutics • Oct 15, 1993 (Issue 907)
may be effective for topical treatment of multiple actinic keratoses, but published data are sparse. A controlled ...
Masoprocol cream 10% (meso-nordihydroguiaretic acid, Actinex - Reed and Carnrick) is now available in the USA for topical treatment of actinic keratoses.
The Female Condom
The Medical Letter on Drugs and Therapeutics • Dec 24, 1993 (Issue 912)
COPYRIGHT LAWS
CONCLUSION — The new female condom, judging from the limited data available, appears ...
A condom for women (Reality - Wisconsin Pharmacal) to prevent pregnancy and sexually transmitted diseases, including AIDS, has been approved for marketing by the US Food and Drug Administration (FDA). Already available in many family planning clinics, it will be available in pharmacies in a few months.
Vinorelbine For Treatment of Advanced Non-Small-Cell Lung Cancer
The Medical Letter on Drugs and Therapeutics • Aug 18, 1995 (Issue 955)
%
and a median survival of 40 weeks (T Le Chevalier et al, J Clin Oncol, 12:360, 1994). Preliminary
data ...
Vinorelbine (Navelbine - Burroughs Wellcome), a semisynthetic vinca alkaloid, has been approved by the US Food and Drug Administration for parenteral use in the treatment of advanced non-small-cell lung cancer (NSCLC). Various combinations of cisplatin (Platinol), vinblastine (Velban, and others), mitomycin (Mutamycin), ifosfamide (Ifex), etoposide (VePesid) and paclitaxel (Taxol) have been used previously for this indication.
Topotecan Hydrochloride for Metastatic Ovarian Cancer
The Medical Letter on Drugs and Therapeutics • Oct 25, 1996 (Issue 986)
OF U.S. AND INTERNATIONAL COPYRIGHT LAWS
CONCLUSION — Although published data are limited, topotecan ...
Topotecan hydrochloride (Hycamtin - SmithKline Beecham) was recently approved by the U.S. Food and Drug Administration for parenteral use as a single agent in patients with metastatic ovarian cancer refractory to other drugs. Initial treatment for metastatic ovarian cancer usually consists of cisplatin (Platinol) or carboplatin (Paraplatin) plus paclitaxel (Taxol) or cyclophosphamide (Cytoxan, and others).